Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hormone Refractory Prostate Cancer × Mycobacterium w vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Hormone Refractory Prostate Cancer 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 3 sargramostim 1 radium Ra 223 dichloride 1 epothilone B 1 bafetinib 1 Sunitinib 1 Prednisone 1 Mycobacterium w vaccine 1 Everolimus 1 Carboplatin 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡